A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Familial Chylomicronemia Syndrome
Interventions
DRUG

Olezarsen

Olezarsen will be administered by SC injection.

Trial Locations (27)

10016

CTSI Investigational Pharmacy, New York

10032

Milstein Hospital, New York

19104

IDS Central, Philadelphia

28041

Hospital Universitario 12 de Octubre, Madrid

33434

Excel Medical Clinical Trials, LLC, Boca Raton

41013

Hospital Universitario Virgen del Rocío, Seville

60068

Department of Pharmacy, Park Ridge

66160

University of Kansas Medical Center (KUMC), Kansas City

69677

Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique, Bron

80131

Via Sergio Pansini 5, Napoli

83101

Metabolicke centrum MU, Bratislava

90127

UOC di Farmacia AOUP PAOLO GIACCONE, Palermo

92648

Diabetes/Lipid Management & Research Center, Huntington Beach

94270

Hôpital Bicêtre, Le Kremlin-Bicêtre

G7H 7K9

Ecogene-21, Chicoutimi

H2W 1R7

Institute de Recherches Cliniques de Montreal, Montreal

Nathalie Saint-Pierre, Montreal

G1V 4W2

Clinique des Maladies Lipidiques de Quebec Inc., Québec

05 13385

Pharmacie Hopital de la Conception, Marseille

00161

Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome

1105 AZ

Academisch Medisch Centrum Goederenontvangst Apotheek t.a.v. Kenniscentrum, Amsterdam

0372

Oslo Hospital Pharmacy Rikshospitalet, Oslo

4835-044

Hospital da Senhora da Oliveira Guimaraes, Creixomil

1340-019

Dra Margarida Falcao Centro Hospitalar Lisboa Ocidental Hospital Egas Moniz, Lisbon

08036

Hospital Clínic Barcelona C/ Villarroel, Barcelona

211 24

Apokteket AB, Malmo

M13 9WL

Royal Manchester Children's Hospital, Manchester

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY